Shots:
- The approval is based on P-lll SUNBEAM & RADIANCE part B study which involves the assessing of Zeposia (0.92mg and 0.46 mg) vs Avonex (qw, IM) in 1,346 & 1313 patients with RMS for 12 & 24mos. across 158 & 150 sites in 20 & 21 countries respectively
- Result: relative reduction in ARR (48% & 38%); absolute ARR (0.18 vs 0.35 & 0.17 vs 0.28). reduction in number of T1– weighted GdE (0.16 vs 0.43 & 0.18 vs 0.37); reduction in enlarging T2 brain lesions (1.47 vs 2.84 & 1.84 vs 3.18) respectively
- Zeposia is the only first line S1P receptor modulator approved in Canada for the treatment of RRMS, acts by decreasing the frequency of clinical exacerbations
Click here to read full press release/ article | Ref: News Wire Canada | Image: ME Support
The post BMS’ Zeposia (ozanimod) Receives Health Canada Approval for Relapsing Remitting Multiple Sclerosis first appeared on PharmaShots.
